|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
September/October 2008FeaturesCover Story Healthcare Reform: How the Candidates’ Positions Indirectly Affect Access to and Financing of High-Tech TherapiesNobody is out on the hustings talking about cost-sharing or fair means of access to biologics. But a pipeline loaded with them may ultimately force the government to address fundamental cost issues in healthcare. How the candidates’ positions play into this. Molecular Diagnostics HER2 Tests: How Do We Choose?Incorrect test results defining HER2 status are not uncommon. Getting it wrong leads to spending a fortune on treatment that won’t work or denying therapy to people whose lives could be spared by it. Cost Management Managing MS: Trends, Issues, and PerspectivesThe nature of multiple sclerosis and its treatment differ from some other conditions that are treated with biologics, leading to opportunities that could help to close gaps in patient care. Care Management High-Tech, Simple Solutions For Improving Patient Care ManagementNonadherence is an incredibly complex and difficult-to-address problem. Several products designed to appeal to tech-savvy patients offer the promise of one simple solution. Cost-Effectiveness Cost-Effectiveness: An Evolving ScienceOverseas, government payers challenge biopharma companies to show evidence of cost-effectivess. Collaboration there could provide a model for U.S. payers and manufacturers. DepartmentsOpeners This Is What MattersWhat really matters, anyway? Editorial Industry ProfileA profile of the pharma industry. At a Glance MS: Prevalence, Economics, and the PipelinePrevalence of disease, economics of care, and implications for payers, as told in charts. Drug Track Research, Conferences, and FDA ActionsApprovals, research, conference coverage. Personalized Medicine Can Online Genetic Testing Predict the Future?Pluses, minuses of online genetic testing. Specialty Pharmacy The Value of Value-Added ServicesThe value of value-added services. Employer to Employer Peeling Back the OnionAn academic setting has its advantages. Health Plan Confidential Is It Time To Take a Harder Look at the QALY?Time to take a harder look at the QALY? Trends: Sales Biologics Sales Trends Nearly Double Those of Traditional PharmaceuticalsBiologic sales growth double the rest. |
|||||